<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 1.6: Metabolic & Cardiovascular Risk Screening | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 border-radius: 0;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border: none;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #f3f4f6;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #92400e;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #7e22ce;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
 margin: 0;
 padding: 0;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
 border-bottom: 1px solid rgba(167, 139, 250, 0.2);
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #7c3aed;
 font-weight: 700;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

p {
 font-size: 17px;
 line-height: 1.85;
 color: #374151;
 margin-bottom: 20px;
}

.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip::before {
 content: 'üí°';
 position: absolute;
 top: -12px;
 left: 24px;
 background: white;
 padding: 4px 8px;
 border-radius: 8px;
 font-size: 20px;
 box-shadow: 0 2px 8px rgba(0,0,0,0.08);
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

.coach-tip p {
 color: #713f12;
 font-size: 15px;
 margin: 0;
 line-height: 1.7;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-icon {
 width: 48px;
 height: 48px;
 background: rgba(255, 255, 255, 0.2);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
}

.case-study-header .title {
 color: white;
 font-weight: 700;
 font-size: 16px;
 margin: 0;
}

.case-study-content {
 padding: 28px;
}

.patient-profile {
 display: flex;
 align-items: center;
 gap: 16px;
 padding: 16px;
 background: #f9fafb;
 border-radius: 12px;
 margin-bottom: 20px;
}

/* DATA TABLE */
.data-table {
 width: 100%;
 border-collapse: collapse;
 margin: 25px 0;
 font-size: 15px;
}

.data-table th {
 background: #722F37;
 color: white;
 padding: 12px 15px;
 text-align: left;
}

.data-table td {
 padding: 12px 15px;
 border-bottom: 1px solid #e5e7eb;
}

.data-table tr:nth-child(even) {
 background: #f9fafb;
}

/* CHECK YOUR UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}

.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}

.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}

.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}

.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}

.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}

.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}

.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES BOX */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box .box-label {
 color: #64748b;
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 font-weight: 700;
 margin-bottom: 16px;
}

.references-box ol {
 list-style: none;
 padding: 0;
 margin: 0;
 counter-reset: ref-counter;
}

.references-box li {
 counter-increment: ref-counter;
 padding: 12px 16px 12px 48px;
 position: relative;
 font-size: 14px;
 color: #475569;
 line-height: 1.7;
 background: white;
 border-radius: 8px;
 margin-bottom: 8px;
 border: 1px solid #e5e7eb;
}

.references-box li::before {
 content: counter(ref-counter);
 position: absolute;
 left: 16px;
 top: 12px;
 width: 22px;
 height: 22px;
 background: #722F37;
 color: white;
 border-radius: 50%;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
}

/* MODULE CONNECTION */
.module-connection {
 background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.module-connection .connection-icon {
 width: 44px;
 height: 44px;
 background: linear-gradient(135deg, #0ea5e9, #0284c7);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 22px;
 flex-shrink: 0;
}

.module-connection .connection-text p {
 margin: 0;
 font-size: 15px;
 color: #0c4a6e;
 line-height: 1.5;
}

 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 1: S: Symptom & Lab Screening</span>
 <h1 class="lesson-title">Metabolic & Cardiovascular Risk Screening</h1>
 <div class="lesson-meta">
 <span class="meta-badge">‚è±Ô∏è 14 min read</span>
 <span class="meta-badge">üìã Lesson 6 of 8</span>
 <span class="meta-badge">üéØ Specialist Level</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">‚úì</div>
 <div class="asi-text">
 <div class="label">AccrediPro Standards Institute Verified</div>
 <div class="title">PCOS & Metabolic Health Specialist‚Ñ¢ Curriculum Standard</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <p class="toc-label">In This Lesson</p>
 <ul class="toc-list">
 <li><a href="#lipid-patterns"><span class="section-num">01</span>The Atherogenic Lipid Profile</a></li>
 <li><a href="#inflammation"><span class="section-num">02</span>hs-CRP & Systemic Inflammation</a></li>
 <li><a href="#hypertension"><span class="section-num">03</span>Hypertension in the PCOS Client</a></li>
 <li><a href="#nafld"><span class="section-num">04</span>NAFLD & ALT/AST Ratios</a></li>
 <li><a href="#uric-acid"><span class="section-num">05</span>Uric Acid: The Emerging Marker</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <div class="connection-icon">üîó</div>
 <div class="connection-text">
 <p>Building on <strong>Lesson 5: Decoding Insulin Resistance</strong>, we now transition from glucose management to the systemic "fallout" of metabolic dysfunction. This lesson identifies the specific cardiovascular and hepatic markers that define long-term risk for the PCOS client.</p>
 </div>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>The "S" in S.T.E.A.D.Y. Method‚Ñ¢: Screening for Future Health</h3>
 <p>As a PCOS Specialist, your role extends beyond helping a client clear her skin or regulate her cycle. You are a <strong>guardian of her metabolic future</strong>. Women with PCOS are at a significantly higher risk for cardiovascular disease and non-alcoholic fatty liver disease (NAFLD), often manifesting decades earlier than their peers. This lesson equips you to screen for these risks using standard and functional lab markers, ensuring your clients don't just feel better today, but stay healthy for a lifetime.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <span class="box-label">Learning Objectives</span>
 <ul>
 <li>Identify the "Atherogenic Lipoprotein Profile" common in PCOS and its clinical significance.</li>
 <li>Interpret hs-CRP levels to quantify systemic inflammation and cardiovascular risk.</li>
 <li>Analyze ALT/AST ratios and their role in screening for Non-Alcoholic Fatty Liver Disease (NAFLD).</li>
 <li>Evaluate the impact of early-stage hypertension and elevated Uric Acid on the PCOS metabolic phenotype.</li>
 <li>Communicate risk factors to clients in an empowering, non-alarmist manner that drives adherence.</li>
 </ul>
 </div>

 <!-- Case Study 1 -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">üë©‚Äçüíº</div>
 <div>
 <p class="title">Case Study: The "Fit" PCOS Client</p>
 </div>
 </div>
 <div class="case-study-content">
 <div class="patient-profile">
 <div>
 <strong>Client:</strong> Sarah, 46 ‚Ä¢ <strong>Occupation:</strong> Former Teacher/Health Coach Pivot ‚Ä¢ <strong>Symptoms:</strong> Mild hirsutism, stubborn midsection weight, "brain fog."
 </div>
 </div>
 <p>Sarah's total cholesterol was 210 mg/dL‚Äîflagged as "high" by her GP. However, her GP didn't look at her <strong>Triglyceride/HDL ratio</strong>, which was 4.2 (Optimal is < 1.5). Despite being active and eating "clean," Sarah's lipid pattern revealed significant insulin resistance and cardiovascular risk. By focusing on the <em>S: Screening</em> phase of the S.T.E.A.D.Y. Method‚Ñ¢, Sarah was able to implement targeted glucose tuning (Module 2) that dropped her TG/HDL ratio to 1.8 in just 90 days.</p>
 </div>
 </div>

 <h2 id="lipid-patterns">The Atherogenic Lipid Profile in PCOS</h2>
 <p>In the conventional model, cholesterol is often viewed through a narrow lens: LDL is "bad," and HDL is "good." However, for the PCOS client, the <em>pattern</em> of lipids is far more predictive than the total numbers. The <span class="highlight">Atherogenic Lipoprotein Profile</span> is a hallmark of PCOS metabolic dysfunction.</p>

 <h3>The TG/HDL Ratio: The Specialist‚Äôs Secret Weapon</h3>
 <p>While total cholesterol may remain normal, insulin resistance drives a specific shift: high triglycerides and low HDL. A 2022 study of over 1,200 women found that the <strong>Triglyceride to HDL ratio</strong> is one of the most accurate surrogates for identifying insulin resistance in PCOS populations.</p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Marker</th>
 <th>Conventional Range</th>
 <th>Specialist Functional Range</th>
 <th>Significance in PCOS</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td>Triglycerides</td>
 <td>< 150 mg/dL</td>
 <td>< 80 mg/dL</td>
 <td>Directly reflects carbohydrate tolerance.</td>
 </tr>
 <tr>
 <td>HDL (The "Protective")</td>
 <td>> 50 mg/dL</td>
 <td>> 60 mg/dL</td>
 <td>Clears cholesterol from arteries; often low in PCOS.</td>
 </tr>
 <tr>
 <td>TG/HDL Ratio</td>
 <td>N/A</td>
 <td>< 1.5 (Optimal)</td>
 <td>> 3.0 indicates significant insulin resistance.</td>
 </tr>
 <tr>
 <td>LDL Particle Size</td>
 <td>N/A</td>
 <td>Pattern A (Large/Fluffy)</td>
 <td>Pattern B (Small/Dense) is highly inflammatory.</td>
 </tr>
 </tbody>
 </table>

 <div class="coach-tip">
 <span class="tip-label">Specialist Income Insight</span>
 <p>Practitioners who can interpret these "hidden" ratios can command higher fees. A standard "Health Coach" might just look at total cholesterol, but a <strong>PCOS & Metabolic Health Specialist</strong> provides a deep-dive Lab Interpretation Session. These sessions typically range from <strong>$250 to $450</strong> as a standalone service for women who already have labs but don't understand them.</p>
 </div>

 <h2 id="inflammation">hs-CRP: Quantifying Systemic Low-Grade Inflammation</h2>
 <p>PCOS is now widely recognized as a state of <span class="highlight">chronic low-grade inflammation</span>. This isn't the acute inflammation you see with a sprained ankle; it is a systemic "fire" that damages the endothelial lining of blood vessels and worsens insulin resistance.</p>

 <p>The <strong>High-Sensitivity C-Reactive Protein (hs-CRP)</strong> is the gold standard for measuring this risk. In women with PCOS, hs-CRP levels are frequently elevated even in the absence of obesity, suggesting that the hormonal environment itself is pro-inflammatory.</p>

 <ul>
 <li><strong>hs-CRP < 1.0 mg/L:</strong> Low risk (Optimal).</li>
 <li><strong>hs-CRP 1.0 - 3.0 mg/L:</strong> Average risk / Moderate systemic inflammation.</li>
 <li><strong>hs-CRP > 3.0 mg/L:</strong> High risk for cardiovascular events and significant metabolic dysfunction.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Clinical Pearl</span>
 <p>Always ask your client if they had a recent cold, injury, or intense workout within 48 hours of their blood draw. hs-CRP is highly sensitive; an acute "flare" can mask the baseline metabolic inflammation you are trying to screen for.</p>
 </div>

 <h2 id="hypertension">Hypertension: The Silent Risk in the PCOS Population</h2>
 <p>High blood pressure (Hypertension) often goes undiagnosed in younger PCOS clients because practitioners don't expect it in women in their 20s or 30s. However, hyperinsulinemia causes the kidneys to <em>retain sodium</em> and stimulates the sympathetic nervous system, both of which drive up blood pressure.</p>

 <p>A meta-analysis of 42 studies (n=8,234) confirmed that women with PCOS have a <strong>70% higher risk</strong> of developing hypertension compared to age-matched controls. Early screening isn't just about the numbers; it's about preventing the arterial stiffening that leads to heart disease later in life.</p>

 <h2 id="nafld">NAFLD: Screening with ALT/AST Ratios</h2>
 <p>Non-Alcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Because the liver is the primary site for insulin clearance, a "fatty" liver cannot efficiently process insulin, creating a vicious cycle of worsening PCOS symptoms.</p>

 <p><strong>The ALT/AST Ratio:</strong> While conventional labs consider an ALT (Alanine Aminotransferase) of 40 U/L "normal," functional specialists look closer. For women, an <strong>ALT above 19-25 U/L</strong> may indicate early stage fat accumulation in the liver. Furthermore, if ALT is higher than AST (ALT/AST ratio > 1), it strongly suggests metabolic liver stress.</p>

 <div class="coach-tip">
 <span class="tip-label">Specialist Tip</span>
 <p>When you see elevated liver enzymes in a PCOS client, don't just think "detox." Think "Sugar." NAFLD is driven primarily by excess fructose and refined carbohydrates. This is where the <em>T: Therapeutic Glucose Tuning</em> phase of our method becomes life-saving.</p>
 </div>

 <h2 id="uric-acid">Uric Acid: The Emerging Metabolic Marker</h2>
 <p>Traditionally associated only with gout, <strong>Uric Acid</strong> is emerging as a critical marker for metabolic health in women. Elevated Uric Acid (Hyperuricemia) is a powerful predictor of insulin resistance and is often a direct indicator of high fructose intake.</p>

 <p>In PCOS, Uric Acid levels > 5.5 mg/dL are associated with:
 <ul>
 <li>Higher levels of visceral (belly) fat.</li>
 <li>Increased risk of developing Type 2 Diabetes.</li>
 <li>Increased oxidative stress in the ovaries, potentially worsening egg quality.</li>
 </ul></p>

 <div class="coach-tip">
 <span class="tip-label">Communication Strategy</span>
 <p>When explaining Uric Acid to a client, say: "Think of Uric Acid as a 'metabolic smoke alarm.' It tells us if your body is struggling to process the sugars and fuels you're taking in. By bringing this number down, we protect your heart and your fertility simultaneously."</p>
 </div>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 
 <div class="question-item">
 <p class="question-text"><strong>1. Which lipid ratio is considered a "Specialist Secret Weapon" for identifying insulin resistance in PCOS clients?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans1')">Reveal Answer</button>
 <div id="ans1" class="answer-text">The <strong>Triglyceride to HDL ratio (TG/HDL)</strong>. A ratio > 3.0 is a strong indicator of insulin resistance, while < 1.5 is considered optimal.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. What is the functional "Specialist" cut-off for ALT in women when screening for early NAFLD?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans2')">Reveal Answer</button>
 <div id="ans2" class="answer-text">While conventional labs allow up to 40 U/L, specialists look for <strong>ALT to be between 19-25 U/L</strong>. Values above this, especially when ALT > AST, suggest metabolic liver stress.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. True or False: hs-CRP only measures cardiovascular risk and has no bearing on PCOS hormonal symptoms.</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans3')">Reveal Answer</button>
 <div id="ans3" class="answer-text"><strong>False.</strong> hs-CRP measures systemic inflammation, which directly worsens insulin resistance and can stimulate the ovaries to produce more androgens, exacerbating PCOS symptoms like acne and hirsutism.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. Why is Uric Acid considered a "metabolic smoke alarm" in the context of PCOS?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans4')">Reveal Answer</button>
 <div id="ans4" class="answer-text">Elevated Uric Acid (> 5.5 mg/dL) is a predictor of insulin resistance, visceral fat accumulation, and high fructose intake, signaling metabolic dysfunction before more severe conditions like diabetes develop.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways for the Specialist</p>
 <ul>
 <li><strong>Look Beyond the Basics:</strong> Standard lipid panels often miss the atherogenic pattern (High TG, Low HDL) that defines PCOS cardiovascular risk.</li>
 <li><strong>Inflammation is the Driver:</strong> hs-CRP levels > 1.0 mg/L indicate systemic inflammation that must be addressed via the S.T.E.A.D.Y. Method‚Ñ¢ to achieve long-term results.</li>
 <li><strong>The Liver-PCOS Connection:</strong> NAFLD is highly prevalent in PCOS; use ALT/AST ratios to screen early and prioritize liver health through glucose tuning.</li>
 <li><strong>Uric Acid Matters:</strong> This "forgotten" marker is a powerful tool for monitoring fructose-driven metabolic dysfunction and oxidative stress.</li>
 <li><strong>Empowerment through Screening:</strong> Use these markers to show clients the "Why" behind their protocols, increasing their commitment to the work.</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>Osibogun, O. et al. (2022). "Triglyceride-to-HDL Cholesterol Ratio and Insulin Resistance in Women with PCOS." <em>Journal of Clinical Endocrinology & Metabolism.</em></li>
 <li>Wild, R.A. et al. (2021). "Cardiovascular Disease Risk in Women with Polycystic Ovary Syndrome." <em>The Lancet Diabetes & Endocrinology.</em></li>
 <li>Rostamtabar, M. et al. (2020). "The Role of Inflammation in Polycystic Ovary Syndrome." <em>Journal of Inflammation Research.</em></li>
 <li>Vasselatou, E. (2018). "Nonalcoholic Fatty Liver Disease and Polycystic Ovary Syndrome." <em>World Journal of Gastroenterology.</em></li>
 <li>Mu, L. et al. (2023). "Serum Uric Acid Levels and Risk of Metabolic Syndrome in PCOS: A Systematic Review." <em>Frontiers in Endocrinology.</em></li>
 </ol>
 </div>
</div>

<script>
function toggleAnswer(id) {
 const el = document.getElementById(id);
 if (el.style.display === 'block') {
 el.style.display = 'none';
 } else {
 el.style.display = 'block';
 }
}
</script>

</body>
</html>